14th Jan 2014 08:52
14 January 2014
REGENERSIS PLC
Issue of new shares, Director shareholdings, New share incentive plan and total voting rights
Regenersis Plc ("Regenersis" the "Company" or the "Group"), a strategic outsourcing partner to many of the world's leading consumer technology companies, announces that on 14 January 2014 it issued 66,117 new ordinary shares of 2 pence each ("Ordinary Shares") at par in satisfaction of the Incentive Share Plan 2 ("ISP2"), which vested on the 30 November 2013. The balance of shares issued to directors and employees pursuant to ISP2 are being transferred from the Company's employee benefit trust ("EBT").
As a result of the vesting of ISP2, the following director's interest in shares has changed as follows:
Name | Position | Shares received |
Jog Dhody | CFO | 100,591 |
Name | Position | Shares sold at 300p per Ordinary Share to settle tax liabilities |
Jog Dhody | CFO | (50,296) |
Following this, Jog Dhody's holding is 405,581 Ordinary Shares, representing 0.81% of the Company's increased issued share capital of 49,781,503 Ordinary Shares.
Application has now been made for the admission of the 66,117 new Ordinary Shares, as referred to above, to be admitted to trading on AIM. The new Ordinary Shares will rank pari passu with the existing issued Ordinary Shares of the Company.
It is expected that admission will become effective and that dealings will commence in the new Ordinary Shares on 17 January 2013 ("Admission"). Following Admission, the Company confirms that its total issued share capital will comprise 49,781,503 Ordinary Shares of 2 pence each. No Ordinary Shares are held in treasury and hence the number of Ordinary Shares with voting rights will be 49,781,503 Ordinary Shares.
The figure of 49,781,503 Ordinary Shares may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of Regenersis under the FSA's Disclosure and Transparency Regime.
The figure of 48,839,340 Ordinary Shares may therefore be used by Shareholders in the basic EPS calculations.
Following consultation with shareholders, the Company has, today, implemented a new incentive and performance arrangement called Incentive Share Plan 3 ("ISP3"), via the award of conditional rights to beneficiaries to acquire Ordinary Shares.
Holders will be entitled to be issued a number of Ordinary Shares (or a cash alternative at the Company's discretion) equal to a percentage of the growth in shareholder value achieved by the Company in the period ending 31 January 2017, above a base value of 324.8 pence per share. This is subject to conditions set by the Remuneration Committee, with provisions for early vesting in the event of a takeover of the Company or if the average mid-market closing share price for any period of 30 consecutive days commencing after 1 May 2015 is greater than 495 pence.
The beneficiaries will include Hanover Investors, Jog Dhody and other employees. The awards made are:
Name | Position | % of total shareholder value growth allocated to beneficiaries |
Hanover Investors* | Executive Chairman** | 7.0% |
Jog Dhody | CFO | 1.25% |
\* This award has been received by Hanover Investors; Matthew Peacock has an indirect interest in this award as a result of his position in Hanover Investors.
**As part of these agreements Hanover Investors will provide, under the terms of a service agreement, business and strategic planning advice to Regenersis and also separately Matthew Peacock in the role of Executive Chairman.
Other employees may be granted entitlements under this new scheme by the Company with a total value of 3.75% such that the total value of the shareholder growth allocated to Directors and employees will not exceed 12% under the ISP3.
Enquiries:
Regenersis PlcMatthew Peacock, Executive ChairmanJog Dhody, Chief Financial Officer | +44 (0) 20 3657 7000 |
Panmure Gordon (UK) Limited (Nomad and Joint Broker)Dominic Morley / Nicola Marrin, Corporate FinanceCharles Leigh Pemberton, Corporate Broking | +44 (0) 20 7886 2500 |
Cenkos Securities (Joint Broker)Stephen Keys, Corporate FinanceAlex Aylen, Sales | +44 (0) 20 7397 8900 |
Tavistock CommunicationsCatriona Valentine / Matt Ridsdale / Keeley Clarke | +44 (0) 20 7920 3150 |
About Regenersis
With its core business in repairing consumer electronics, Regenersis helps companies like HTC, Nokia, Samsung, Orange, John Lewis, LG, Toshiba and others deliver the best possible after market service to its customers. Through the provision of technical call centres or managing returns and repairs, the company supports a wide range of products including mobile phones, laptops and tablets, set top boxes, televisions and other electronic equipment. Regenersis also operates in the business-to-business environment where it offers high quality and secure repair and refurbishment solutions for chip and pin devices, ATMs and even MRI scanners.
Building upon its success in repair, the company is already proving its pioneering range of services known as Advanced Solutions, which include in-field testing, where Regenersis is partnering with cable operators across the world to diagnose set-top box faults in the home, reducing unnecessary returns. The newly formed Renew business unit comprises Digital Care, which provides extended warranty and insurance services to end customers; Refurbishment, which provides legitimate, quality refurbished components and devices to the end customer; and Recommerce, which offers client led refurbishment, repair and onward disposition of devices.
www.regenersis.com
Related Shares:
BLTG.L